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Abstract
The identification of germline variants predisposing to hereditary nonpolyposis colorectal cancer (HNPCC) is crucial
for clinical management of carriers, but several probands remain negative for such variants or bear variants of
uncertain significance (VUS). Here we describe the results of integrative molecular analyses in 132 HNPCC patients
providing evidences for improved genetic testing of HNPCC with traditional or next generation methods. Patients
were screened for: germline allele-specific expression (ASE), nucleotide variants, rearrangements and promoter
methylation of mismatch repair (MMR) genes; germline EPCAM rearrangements; tumor microsatellite instability (MSI)
and immunohistochemical (IHC) MMR protein expression. Probands negative for pathogenic variants of MMR genes
were screened for germline APC and MUTYH sequence variants. Most germline defects identified were sequence
variants and rearrangements of MMR genes. Remarkably, altered germline ASE of MMR genes was detected in 8/22
(36.5%) probands analyzed, including 3 cases negative at other screenings. Moreover, ASE provided evidence for
the pathogenic role and guided the characterization of a VUS shared by 2 additional probands. No germline MMR
gene promoter methylation was observed and only one EPCAM rearrangement was detected. In several cases,
tumor IHC and MSI diverged from germline screening results. Notably, APC or biallelic MUTYH germline defects
were identified in 2/19 probands negative for pathogenic variants of MMR genes. Our results show that ASE
complements gDNA-based analyses in the identification of MMR defects and in the characterization of VUS affecting
gene expression, increasing the number of germline alterations detected. An appreciable fraction of probands
negative for MMR gene variants harbors APC or MUTYH variants. These results indicate that germline ASE analysis
and screening for APC and MUTYH defects should be included in HNPCC diagnostic algorithms.
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Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC), also
known as Lynch syndrome, is the most frequent form of
autosomal dominant predisposition to colorectal cancer (CRC)
[1]. Genetic diagnosis of germline defect carriers in affected
families is fundamental for an efficient clinical surveillance and
allows targeted chemoprevention that was recently shown to
substantially reduce cancer incidence in these patients [2].
However, the identification of pathogenic germline defects in
this syndrome is not trivial, as reflected by the wide fluctuation
in the rate of genetic alterations identified in different studies
and by the relevant number of variants with uncertain
significance (VUS) detected [3-6]. The variable rate of
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alterations detected reflects in part differences in sensitivity of
the molecular methods utilized and in part the fact that clinical
diagnosis does not completely account for the underlying
genetic heterogeneity, even when the selection of probands is
based on strict Amsterdam criteria I (AC-I) or Amsterdam
criteria II (AC-II) [7]. The majority of HNPCC patients are linked
to germline mismatch repair (MMR) defects and develop
tumors with high levels of microsatellite instability (MSI-H), the
hallmark of MMR deficiency. Germline MLH1 or MSH2 variants
are identified in most of these patients, whereas variants in
other MMR genes are detected in a smaller fraction of cases
[1-6]. Notably, also germline deletions affecting the 3’ end of
the epithelial cell adhesion molecule gene (EPCAM) may
cause HNPCC through hypermethylation and silencing of the
downstream MSH2 promoter in EPCAM-expressing tissues [8].
EPCAM deletions were reported at a relatively high frequency
(16-21%) in different studies conducted in cases negative for
germline MMR defects [9,10]. The highest frequency (up to
33%) of EPCAM rearrangements was observed in the subset
of MSI-H patients negative for germline MMR alterations and
lacking MSH2 tumor expression [11,12], but the overall
frequency of these rearrangements in series of HNPCC
probands, unselected for mutational status or MSH2 tumor
immunostaining, has not been evaluated.
In addition to MMR genes and EPCAM, other genes play a
role in this genetically heterogeneous syndrome. A relatively
high proportion of families meeting AC has “familial colorectal
cancer type X” (FCCTX), a colorectal cancer aggregation with
no evidence of germline or tumor-associated MMR defects [4].
For the majority of these families, the genetic alteration
responsible for colon cancer predisposition is not known,
although defects in non-MMR genes, such as MUTYH, OGG1
or BMPR1A, are occasionally detected [13-15]. In this regard,
also APC variants associated to very attenuated phenotypes
may overlap with HNPCC [16], further widening the range of
CRC predisposing genes to be screened.
Based on the above considerations, traditional genetic
testing in HNPCC focused on the analysis of MMR genes and
several diagnostic algorithms were proposed to optimize this
screening [17-21]. However, these algorithms may limit the
sensitivity of genetic testing, underestimating carriers of
pathogenic variants in MMR genes. Recently, a highly
processive gDNA assay (ColoSeq, University of Washington,
Seattle, WA) based on targeted capture and next-generation
sequencing (NGS) was designed to simultaneously analyze
MMR-related and -unrelated genes in HNPCC [22]. NGS-
based testing can overcome some of the limitations of low-
throughput methods, but even this approach has some
drawbacks. For instance, NGS does not provide insights into
the pathogenic role of VUS that are more likely to be detected
by these highly processive methods. Moreover, genomic-based
approaches are not designed to define the pathogenic potential
of cis- and trans-acting variants that affect gene expression.
These limitations might be in part overcome by cDNA-based
assays, such as the analysis of allele-specific expression
(ASE) that has the potential to uncover germline defects
predisposing to colorectal cancer even when a pathogenic
variant has not been ascertained or the role of the variants
detected is unclear [23-27].
In the present study, we illustrate the results of integrative
analyses conducted on a series of 132 Italian HNPCC patients
using previously developed and novel assays for the screening
of germline and tumor defects. We show that germline ASE
analysis complements gDNA-based assays in the identification
and characterization of defects predisposing to CRC. Our
integrative approach also shows that inclusion of MUTYH and
APC in the screening increases the number of pathogenic
variants detected. Considering the number of patients
analyzed, the panel of genes screened and the range of
methods employed, this study provides indications for clinical
translation of HNPCC genetic testing that may be applied to
traditional or NGS approaches. In particular, our results support
the inclusion of ASE analysis and screening of polyposis genes
in algorithms for genetic diagnosis of HNPCC.
Materials and Methods
Patients and integrative screening strategy
We studied 132 unrelated AC-I or AC-II patients previously
recruited at different Italian institutions. DNA and RNA were
extracted as previously described [25]. All study participants
gave written informed consent after verbal counseling and the
study was approved by the Ethics Committee of the University
of Chieti. Tumor MSI and IHC analyses were conducted in
probands with available tumor samples. All patients,
irrespective of the results of tumor MSI and IHC analyses,
underwent screening for germline nucleotide substitutions in
MMR genes as detailed below. Probands negative for
pathogenic nucleotide substitutions were further tested for
extended germline rearrangements in MSH2, MLH1 and
EPCAM, followed by screening for germline MSH2 and MLH1
promoter methylation. ASE analyses of MMR genes were
performed in patients with available RNA and heterozygous for
at least one allelic marker, independently from the results of the
above screenings. Patients negative at the above analyses
were tested for APC and MUTYH sequence variants as
described below. The variation data identified in this study have
been submitted to the International Society for Gastrointestinal
Hereditary Tumours (InSiGHT, http://www.insight-group.org/
variants/database/) database.
Screening for germline nucleotide substitutions in
MMR genes
Patients were initially screened for sequence variants in
MSH2 and MLH1 using single strand conformation
polymorphism (SSCP) analysis or denaturing gradient gel
electrophoresis (DGGE). All cases negative at SSCP or DGGE
were further screened for variants in MSH2, MLH1 and MSH6
by denaturing high performance liquid chromatography
(dHPLC) and automated sequencing, which detected a few
additional mutations escaped at the initial screening (data not
shown). To predict potential deleterious effects of novel VUS
we used the following in silico tools: PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/),
HSF (http://www.umd.be/HSF/), FruitFly (http://www.fruitfly.org/
ASE in Integrative HNPCC Testing
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e81194
seq_tools/splice.html), Mutation Taster (http://
www.mutationtaster.org/), Alamut (http://www.interactive-
biosoftware.com). We also used MAPP-MMR (http://
mappmmr.blueankh.com/) and PON-MMR (http://bioinf.uta.fi/
PON-MMR/) prediction algorithms that were specifically
validated for missense variants in MMR genes.
Analysis of extended germline rearrangements in
MSH2, MLH1 and EPCAM
Genomic MSH2 and MLH1 rearrangements were screened
by multiplex ligation-dependent probe amplification (MLPA) in
78 patients negative at initial analysis for pathogenic sequence
variants or with VUS. Confirmation of rearrangements was
obtained by non-fluorescent multiplex PCR coupled to HPLC
(NFMP-HPLC) or by lab-on-a-chip technology for the analysis
of copy number variations (LOC-CNV), as previously described
[28,29]. Since the original version of the MSH2/MLH1 MLPA kit
(SALSA P003, MRC-Holland, Amsterdam, The Netherlands)
employed did not include probes corresponding to EPCAM, we
developed 3 novel NFMP-HPLC assays for screening and
confirmation of genomic rearrangements affecting the 3’ end of
EPCAM and the intergenic MSH2-EPCAM region (Table S1).
These assays were performed in a subset of 33 cases with
VUS or negative at previous screenings and for whom DNA
had not been used up in previous analyses. Breakpoint
analysis was performed as previously described [28,29].
Germline MSH2 and MLH1 promoter methylation
Bisulphite DNA conversion was performed in in 44 cases
negative at initial screening for pathogenic sequence variants
and genomic rearrangements using the Imprinting DNA
modification kit (SIGMA, Saint Louis, MO), according to the
manufacturer's instructions. Screening for germline MLH1
promoter methylation was conducted by methylation-specific
PCR (MSP) using a degenerate and a methylation-specific
primer designed by Suter et al [30]. Furthermore, we designed
a control PCR in which the degenerate primer used for MSP
was paired to a primer specific for unmethylated DNA (Table
S2). DNA from the SW48 cell line was used as positive MLH1
promoter methylation control. Screening for germline MSH2
promoter methylation was conducted by MSP using primers
specific for methylated and unmethylated alleles, as described
by Chan et al [31]. Positive controls for MSH2 promoter
methylation were obtained using control DNAs that had been
universally methylated using S-adenosylmethionine (SAM) and
M.SssI CpG methyltrasferase (New England BioLabs, Ipswich,
MA).
ASE analysis
ASE analyses of MSH2, MLH1 or MSH6 were performed by
primer extension in patients with available RNA and
heterozygous for at least one allelic marker, independently
from their mutational status. ASE analyses were carried out as
previously described using either 32P-labeled or unlabeled
primers coupled to analysis by Molecular Imager (Bio Rad
Laboratories, Hercules, CA) or by DHPLC (Transgenomic,
Omaha, NE), respectively [23,25]. Three ASE assays were
performed both with 32P-labeled primers and with the DHPLC-
based method, which yielded comparable results (Table S3).
For each ASE assay, the mean ratio obtained with gDNA
templates was employed to normalize the data generated in
primer extension experiments conducted using cDNA
templates. These normalized cDNA/gDNA ratios were
designated as ASE values. Based on previous studies, only
marked imbalances in relative allele expression corresponding
to twofold imbalances in allelic ratios (<1:2 or >2:1 ratios,
equivalent to ASE values <0.5 or >2, respectively) were
conservatively considered evidence of a pathogenic alteration
[23,25,26]. These ASE values deviate more than 3 SDs from
mean values observed in heterozygous controls for two CRC
predisposing genes that we have previously analyzed based on
the availability of ASE markers frequent in the Italian population
(ASE of MLH1 in controls, mean 1.04, SD 0.11, using
rs1799977; ASE of APC in controls, mean 1.25, SD 0.21, using
rs2229992) [24,25].
Overall, ASE in MLH1, MSH2 and MSH6 was measured
using 8 previously described [23,25] and 3 novel assays.
Primers for novel assays are described in Table S4.
Tumor MSI and IHC analyses
Tumor assays were performed at the collaborating
institutions that recruited the patients. MSI was analyzed in
most of the probands (93/102) with available tumor samples,
according to international guidelines [32].
Immunohistochemical expression of MSH2, MLH1 and MSH6
proteins was analyzed for 73/102 cases with available tumor
samples as previously described [13].
Screening for APC and MUTYH nucleotide
substitutions
The coding sequence and intron-exon borders of APC and
MUTYH were analyzed by direct sequencing in 19 probands
negative at MMR gene screening. These patients were
selected based on availability of DNA and on the presence of
at least one polyp at diagnosis in the probands and/or in their
relatives.
Results
Multiple approaches were used to analyze 132 unrelated
HNPCC patients for pathogenic defects in MMR and non-MMR
genes.
MSH2, MLH1 and MSH6 nucleotide variants
We detected 41 previously described and 15 novel MMR
gene variants (Table 1 and Table S5). These included 27 loss-
of-function nucleotide changes (nonsense and frameshift)
introducing premature termination codons (PTCs), 14 variants
located at splice sites, 3 in-frame deletions and 12 missense
substitutions. Eight of the splice site variants were
experimentally verified to associate with altered splicing,
including 7 analyzed in previous studies [33-38] and 1 in the
present study (see below), while 5 were considered pathogenic
being located at the almost invariant dinucleotides at intron
ends (Table 1 and Table S5). Two in-frame deletions and 9
missense variants were reported as pathogenic or potentially
ASE in Integrative HNPCC Testing
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pathogenic based on in silico analyses, functional assays,
qualitative classifier or multifactorial prediction model in
previous reports [39-44], as specified in Table S5.
We performed in silico analyses to infer the functional effect
of 4 variants (3 missense and 1 intronic) for which no such
information was available from previous reports. For the 3
novel missense variants a deleterious effect on protein function
was predicted by in silico tools including PON-MMR and
MAPP-MMR (Table S5). In silico tools indicated a potential
effect on splicing for the novel intronic variant (MLH1 c.
1731+4AG) (see below) (Table S5). An additional variant, the
novel MSH2 in-frame deletion (c.2519_2530del12,
p.Val840_Cys843del), was considered potentially pathogenic
because it removes 4 amino acid residues highly conserved in
other species and is located in the ATPase domain of the
MSH2 protein, where variations were previously reported to
cause defects in mismatch binding or release [45,46].
One patient (814#/DGR) was found to carry two missense
substitutions in MSH2 (c.376GA and c.2251GC) predicted to
be pathogenic (see Table S5). Unfortunately, no relatives of
this patient were available for gene testing and the phase of the
two variants could not be ascertained.
Overall, screening for sequence variants in HNPCC related
genes allowed the detection of 56 different substitutions with a
definite or potential pathogenic significance in 72 patients,
including 26 in MLH1 (46.5%), 28 in MSH2 (50%) and 2 in
MSH6 (3.5%) (Table 1 and Table S5).
Genomic rearrangements of MSH2, MLH1 and EPCAM
Screening of MLH1 and MSH2 by MLPA, followed by
confirmatory tests using LOC-CNV and/or NFMP-HPLC,
indicated the presence of genomic rearrangements (including
14 deletions and 1 duplication) in 15 of the 78 patients
analyzed (19%) (Table 1 and Table S6). The gene affected by
the rearrangement was MSH2 in 10 probands (13%) and MLH1
in 5 probands (6.5%). EPCAM rearrangements were screened
by NFMP-HPLC in patients without detectable pathogenic
variants or with VUS. Furthermore, EPCAM rearrangements
were evaluated in 3 patients (476#R26, 459#2809 and
412#3342) that based on MLPA and NFMP-HPLC screening
had evidence of MSH2 deletions involving the first exon of the
gene (Table S6). One of these patients (476#R26) had a
deletion of MSH2 exons 1-6 and NFMP-HPLC-based EPCAM
assays indicated that the rearrangement did not extend to the
EPCAM-MSH2 intergenic region (Table S6). In another patient
(459#2809), previously reported to have a deletion spanning
exons 1-8 of MSH2 [28], EPCAM assays showed that the
deletion included the MSH2 5’ upstream region, but spared the
3’ end of EPCAM (Figure S1). In the third patient (412#3342)
the deletion affected all EPCAM exons included in the EPCAM
assays (exons 3, 8 and 9) (Figure S1). This deletion extended
up to exon 7 of MSH2, as indicated by MLPA and NFMP-HPLC
(Table S6). No EPCAM rearrangements were detected in the
other patients analyzed. All MLH1, MSH2 and EPCAM
rearrangements were confirmed by at least 2 independent
assays based on MLPA, NFMP-HPLC or LOC-CNV. In 9 cases
confirmation of the rearrangements could be also obtained by
Table 1. Overview of MSI, IHC and mutational status in 132










LCH-1 I MSI-H MLH1 MLH1 c.301GA (p.Gly101Ser)  
GDLM-2#III-1 I MSI-H MSH2 MSH2 c.942+3AT  
GDLM-7#III-3 I MSI-H MLH1/MSH2 MSH2 Del exon 7  
LCH-8 I MSI-H MSH2   
GDLV-11#II-9 I MSI-H MLH1   
96#1636 II MSI-H MLH1   





GDLG-18#III-19 I MSI-H n.i. MSH2 Del exon 3  
LCH-19 I MSI-H MSH2 MSH2 c.2245GT (p.Glu749*)  
GDLG-20#II-1 I MSI-H MLH1  MLH1
LCH-27 I MSI-H MSH2  MLH1
GDLG-49#IV-2 I MSI-H MSH2 MSH2 c.1024GA (p.Val342Ile)  
GDLV-52#II-2 I MSI-H MLH1  MLH1
LCH-57 I MSI-H MLH1 MLH1 c.1989GT(p.Glu663Asp)  
LCH-58 I MSI-H MSH2 MSH2 c.2005+3_2005+14del12  
LCH-59 I MSI-H MSH2 MLH1 c.1679delT(p.Phe560Serfs*31)  
LCH-88 I MSI-H n.a. MLH1 c.1731GA(p.Ser577Ser)  
LCH-93 II MSI-H n.a. MSH2 c.1046CG(p.Pro349Arg)  
19#719 II MSI-H MSH2 MSH2 c.1444dupA(p.Arg482Lysfs*6)  
297#875 I MSI-H MLH1 MLH1 c.1852_1854delAAG(p.Lys618del)  
307#2619 I MSI-H MLH1 MLH1 c.199GA (p.Gly67Arg)  
309#3478 I MSI-H MSH2 MSH2 Del exons 9-10  
311#2042 I MSI-H n.i. MLH1 c.731GA (p.Gly244Asp)  
338#1489 I MSI-H MLH1/MSH6 MLH1 c.382GC (p.Ala128Pro)  
349#1581 I MSI-H MSH2 MSH2 c.942+3AT  
363#2541 I MSI-H MSH2 MSH2 Del exons 9-10  
412#3342 II MSI-H MSH2 EPCAM Del exon 3 - MSH2exon 7  
459#2809 I MSI-H MSH2 MSH2 Del 5'upstream region -exon 8  
476#R26 I MSI-H MSH2 MSH2 Del exons 1-6  
667#2412 I MSI-H MSH2 MSH2 c.942+3AT  
668#2371 I MSI-H MLH1 MLH1 c.545+3AG  
670#2413 I MSI-H MLH1 MLH1 c.1989GT(p.Glu663Asp)  
727#AA I MSI-H MSH2 MSH2 c.942+2TA  
814#DGR I MSI-H n.a. MSH2 c.[376GγA(;)2251G>C](p.[Gly126Ser(;)Gly751Arg])  
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986#3487 I MSI-H MLH1 MLH1 c.1731+4AG  
1068#3015 I MSI-H MLH1 MLH1 c.1050delA(p.Gly351Aspfs*16)  
1070#2957 I MSI-H MSH2 MSH2 c.2287G>C(p.Ala763Pro)  
1080#2974 II MSI-H n.a. MSH2 c.2089CT(p.Cys697Arg)  
1251#3260 II MSI-H MSH2 MSH2 c.374C>T (p.Gln125*)  
1256#3479 II MSI-H MSH2 MSH2 c.1786_1788delAAT(p.Asn596del)  
1293#3286 I MSI-H MLH1 MLH1 Del exon 6  
1301#3323 II MSI-H MSH2 MSH2 c.2519_2530del12(p.Val840_Cys843del)  
1459#3324 II MSI-H MLH1 MLH1 c.1852_1854delAAG(p.Lys618del)  
LES1#LP II MSI-H n.a. MLH1 c.731GA (p.Gly244Asp)  
298#668/1584 I MSI-H MSH2 MSH2 c.1077-2A>C  
319#1004 I MSI-H MSH2 MSH2 c.1046CG(p.Pro349Arg)  
350#1933 I MSI-H MLH1 MLH1 c.676CT (p.Arg226*)  
360#2916 I MSI-H MLH1/MSH6 MLH1 c.1731+4AG MLH1
903#2630 II MSI-H MSH2 MSH2 Del exon 3  
1218#3238 I MSI-H MLH1 MLH1 Dup exons 2-3  
1515#3442 II MSI-H MSH2 MSH2 c.1255CT (p.Gln419*)  
334#1170 I MSI-H MSH2 MSH2 c.278_279delTT(p.Leu93Profs*6) MSH2
711#2495 II MSI-H MLH1 MLH1 c.1459CT (p.Arg487*)  
1205#BA II MSI-H MLH1 MSH2 c.1215CA (p.Tyr405*)  
1206#GE I MSI-H MSH2 MSH2 c.1046CG(p.Pro349Arg)  
357#2038 I MSI-H n.a. MSH2 c.2294delC(p.Ala765Valfs*47)  
600#2237 I MSI-H n.a. MSH2 Del exons 4-6  
1138#3149 I MSI-H n.a. MLH1 c.1852_1854delAAG(p.Lys618del)  
737#2838 I MSI-H n.a. MLH1 c.1989GT(p.Glu663Asp)  
TO9726 I MSI-H n.a. MLH1 c.2040CA (p.Cys680*)  
GE9804 I MSI-H n.a. MSH2 c.1705_1706delGA(p.Glu569Ilefs*2)  
GE9726 I MSI-H n.a. MSH2 c.2536CT (p.Gln846*)  
SI9744 I MSI-H n.a. MSH2 c.942+3AT  
GE9914 I MSI-H n.a. MLH1 c.677+1GA  
F102 I MSI-H n.a. MLH1 c.546-2A>G  
SI9606 I MSI-H n.a. MLH1 c.911AT (p.Asp304Val)  
LCH-4 I MSI-H n.i.   
LCH-12 I MSI-H n.i.   
LCH-85 I MSI-H n.a.   











871#R08 I MSI-H n.a.   
GE0101 I MSI-H n.a.   
GE9801 I MSI-H n.a.   
GE9903 II MSI-H n.a.   
LCH-6 I MSS n.a.   
LCH-13 I MSS n.i.   
LCH-79 I MSS n.a.   
296#776 I MSS n.i.   
303#2547 I MSS n.i.   





313#1381 I MSS n.a.   
342#2803 I MSS n.i.   
365#2192 II MSS n.a.   
368#2506 I MSS n.i.   
369#2169 I MSS n.a.   
370#3105 I MSS n.i. APC c.1100_1101delCT(p.Ser367Cysfs*10)  
633#3114 I MSS n.i.   
728#2509 I MSS n.i.   
818#2543 I MSS n.i.   
933#R14 I MSS n.a.   
1165#3159 I MSS n.i.   
1193#3187 I MSS n.i.   
SV0001 I MSI-L n.a.   
TO9913 I n.a. MLH1   
705#3035 I n.a. MLH1 MLH1 c.1367C>A (p.Ser456*)  
1008#2829 I n.a. MSH2 MSH2 c.1757C>G (p.Ser586*)  
1077#2979 I n.a. MLH1 MLH1 c.453+1GA  
1420#3343 II n.a. MSH2 MSH2 c.868GT (p.Glu290*)  
LCH-15 I n.a. n.i. MLH1 c.1918CT(p.Pro640Ser)  
LCH-23 II n.a. n.a. MSH2 Del exon 1  
GDLG-29#III-8 II n.a. n.a. MLH1 c.1852_1854delAAG(p.Lys618del)  
GDLG-31#III-11 I n.a. n.a. MLH1 c.954delC(p.His318Glnfs*49) MLH1
LCH-86 I n.a. n.a. MSH2 c.212-1G>A  
83#3103 I n.a. n.a. MLH1 Del exon1 MLH1
601#2307 I n.a. n.a. MSH6 c.3013CT (p.Arg1005*)  
1157#834 I n.a. n.a. MSH2 c.119delG(p.Gly40Alafs*24)  
324#R10 I n.a. n.a. MLH1 c.1896GA(p.Glu632Glu)  
337#2224 I n.a. n.a. MLH1 c.1989GT(p.Glu663Asp)  
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breakpoint analysis or RT-PCR (Table S6), as previously
reported [28,29].
Germline promoter methylation
Germline MMR gene promoter methylation was analyzed in
cases negative at initial screening for pathogenic nucleotide
variants and genomic rearrangements. CpG promoter
methylation was observed only with positive control DNAs
(SW48 cell line for MLH1 and universally methylated control











463#3031 I n.a. n.a. MLH1 c.1852_1854delAAG(p.Lys618del)  
602#2416 I n.a. n.a. MLH1 c.1011delC(p.Asp338Ilefs*29)  
985#2683 I n.a. n.a. MLH1 Del exon 6  
1074#3001 I n.a. n.a. MSH2 c.1059delG(p.Asn354Thrfs*3)  
1200#3221 I n.a. n.a. MSH6 c.738_741delAAAA(p.Lys246Asnfs*32)  
GE0201 I n.a. n.a. MSH2 Del exon16  
GE9911 I n.a. n.a. MLH1 c.1011delC(p.Asp338Ilefs*29)  
TO0012 I n.a. n.a. MLH1 c.1888_1892delATTGA(p.Ile630*)  
TO0225 I n.a. n.a. MLH1 c.2040CA (p.Cys680*)  
GE0410 I n.a. n.a. MSH2 c.942+3AT  
GE0330 I n.a. n.a. MSH2 c.1216CT (p.Arg406*)  
162#2696 I n.a. n.a. MLH1 c.1559-2A>G  
LCH-10 I n.a. n.i.   
LCH-16 I n.a. n.a.   
LCH-51 I n.a. n.a.   
LCH-53 I n.a. n.a.   
54#982 I n.a. n.i.   
314#1200 I n.a. n.i.   
353#1114 I n.a. n.a.   
455#2186 I n.a. n.a.   
1082#2982 I n.a. n.a.   
F435 I n.a. n.a.   
GE0002 I n.a. n.a.   
na, data not available; ni, IHC not informative.
a. Novel variants are in bold. Germline MMR gene defects for some patients have
been previously reported (see Table 2 and Tables S3, S5, S6 and S7). We also
detected several variants previously reported as nonpathogenic (see Table S5).
b. ASE value <0.5 or >2.
doi: 10.1371/journal.pone.0081194.t001
Germline ASE analysis
Among the 22 patients that could be analyzed, we observed
altered germline ASE of MLH1 in 6 patients and of MSH2 in 2
patients (Table 2 and Table S7). Of these patients, 2 showed
monoallelic expression of MLH1 (GDLV-52#II-2 and 83#3103)
and 6 had markedly imbalanced expression of MLH1
(360#2916, GDLG-20#II-1, GDLG-31#III-11 and LCH-27, mean
ASE values 4.7, 2.01, 2.24 and 2.64, respectively) or MSH2
(GDLM-9#II-2 and 334#1170, mean ASE values 3.58 and 9.20,
respectively). The remaining patients had modestly imbalanced
or balanced ASE (Table 2 and Table S7). ASE values
observed in the 22 probands are depicted in Figure 1. For
reference, the figure depicts also the values that we have
previously measured in control individuals heterozygous for the
frequent c.655AG variant (rs1799977) of MLH1 [25].
Three patients with altered germline ASE (GDLG-31#III-11,
83#3103 and 334#1170) were known carriers of MLH1 or
MSH2 deletions. Conversely, in 2 patients with imbalanced
ASE initial screening for pathogenic variants by SSCP or
DGGE was negative, but subsequent re-analysis by DHPLC
and sequencing identified a frameshift of MSH2 (case
GDLM-9#II-2) and an intronic MLH1 variant with a potential
effect on splicing (case 360#2916, see below) (Table 1 and
Table S7). Overall, variants with a clear or potential pathogenic
role were detected in 5 of the 8 patients with imbalanced ASE
(Table 1 and Table S7), whereas in 3 patients (GDLG-20#II-1,
LCH-27 and GDLV-52#II-2) altered ASE was the only germline
defect detected [23,25].
Analysis of a novel putative splicing variant
In silico analysis by different splice prediction software tools
(see Methods) indicated that the effect of the novel MLH1 c.
1731+4AG variant shared by 2 probands (360#2916 and
986#3487) was uncertain. However, they suggested that this
change might affect splicing by decreasing the strength of the
donor site (average decrease 13%, range 7.4-22%). The
availability of cDNA in patient 360#2916 allowed us to test
whether the c.1731+4AG variant was associated to a splicing
defect. This alteration was elusive at initial testing of RT-PCR
amplified cDNA because only wildtype transcripts were
revealed by direct sequencing or by electrophoretic analysis
(data not shown). However, based on the results of ASE
analysis showing a marked imbalance in allelic expression
(average normalized allelic ratio 4.7, derived from radioactive
and DHPLC-based assays, Table S3), we hypothesized that an
altered splicing might be revealed by DHPLC. As predicted, the
more sensitive DHPLC analysis allowed the detection of a
major peak with a retention time corresponding to the wildtype
transcript and of a minor peak corresponding to a less
expressed shorter transcript. Sequencing confirmed that the
less expressed MLH1 transcript carried an out-of-frame exon
15 skipping (Figure S2).
Tumor MSI and IHC
Among the 93 cases screened for MSI (Table 1), 74 cases
(79.5%) were MSI-H and 19 cases were MSS or MSI-L
(20.5%). Germline MMR gene defects, including sequence
variants, genomic rearrangements or altered ASE were
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identified in most cases (63/74, 85%) with MSI-H tumors (Table
1). No germline MMR gene alteration was detected in MSS or
MSI-L cases.
MLH1, MSH2 or MSH6 protein immunohistochemistry was
available for 73 cases and loss of at least one MMR protein
was detected in 53 cases (72.6%). Lack of expression affected
MLH1 in 21 cases and MSH2 in 29 cases. Moreover, in 1 case
(GDLM-7#III-3) IHC showed the loss of both MLH1 and MSH2,
whereas in other 2 cases (338#1489 and 360#2916) IHC
indicated the loss of both MLH1 and MSH6. We observed
discrepancies between the results of IHC and those of other
analyses in 12 patients. Among the 20 cases displaying normal
MMR protein expression by IHC, 2 cases (LCH-4 and LCH-12)
displayed tumor MSI-H phenotype, one case (GDLG-18#III-19)
carried a germline deletion of MSH2 exon 3 and 2 cases
(311#2042 and LCH-15) carried missense MLH1 variants (c.
731GA and c.1918CT, respectively) previously reported as
potentially pathogenic based on functional or in silico analyses,
respectively (Table 1) [41,42]. Furthermore, in 2 patients
(LCH-59 and LCH-27) IHC indicated the loss of MSH2
expression, but molecular screening revealed germline MLH1
defects, including a frameshift and a markedly imbalanced
ASE, respectively (Table 1). In one additional patient
(1205#BA) IHC indicated the loss of MLH1 expression,
whereas sequencing revealed a nonsense variant in MSH2
(Table 1 and Table S5). Finally, in 4 cases IHC indicated the
loss of either MSH2 (patient LCH-8) or MLH1 (patients
GDLV-11#II-9, 96#1636 and TO9913), but no pathogenic
variants in MMR genes were detected.
Figure 1.  ASE values observed.  ASE values between the 2
dashed lines correspond to less than twofold imbalances in
allelic ratios (see Methods).
doi: 10.1371/journal.pone.0081194.g001
Table 2. Results of primer extension ASE analyses performed in this study.
Patientsa Pathogenic germline variants ASE analysis
 Gene ASE marker Consequence Normalized ASE value (SE)b
GDLM-2#III-1 MSH2 c.942+3AT MLH1 c.655AG p.Ile219Val 1.00 (+0.07)
LCH-8 MSH2 c.984CT p.(=) 1.09 (+0.07)
 MLH1 c.655AG p.Ile219Val 0.97 (+0.16)
GDLG-18#III-19 MSH2 Del exon 3 MLH1 c.655AG p.Ile219Val 0.91 (+0.10)
LCH-27 MLH1 c.655AG p.Ile219Val 2.64 (+0.38)
GDLG-31#III-11 MLH1 c.954delC (p.His318Glnfs*49) MLH1 c.655AG p.Ile219Val 2.24 (+0.07)
LCH-51 MLH1 c.655AG p.Ile219Val 0.84 (+0.10)
LCH-59 MLH1 c.1679delT (p.Phe560Serfs*31) MLH1 c.655AG p.Ile219Val 0.97 (+0.11)
GE9804 MSH2 c.1705_1706delGA (p.Glu569Ilefs*2) MLH1 c.655AG p.Ile219Val 1.09 (+0.05)
96#1636 MLH1 c.655AG p.Ile219Val 1.17 (+0.06)
334#1170 MSH2 c.278_279delTT (p.Leu93Profs*6) MSH2 c.278_279delTT p.Leu93Profs*6 9.20 (+3.97)
359#2578 MLH1 c.1639_1643dupTTATA (p.Leu549Tyrfs*44) MLH1 c.655AG p.Ile219Val 1.33 (+0.04)
314#1200 MLH1 c.655AG p.Ile219Val 1.01 (+0.03)
1082#2982 MLH1 c.655AG p.Ile219Val 1.07 (+0.02)
 MSH6 c.540TC p.(=) 1.10 (+0.12)
83#3103c MLH1 Del exon 1 MLH1 c.655AG p.Ile219Val Loss of G allele
a. In Table S7 we summarize the results of ASE analyses for additional 8 patients included in the present study, whose ASE results had been previously reported [23,25].
b. Markedly imbalanced ASE values are in bold.
c. For this patient PE analysis performed in the present study confirmed the loss of expression for the G allele previously shown by cDNA sequencing [28].
doi: 10.1371/journal.pone.0081194.t002
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APC and MUTYH screening in probands negative for
germline MMR defects
Germline defects in polyposis-associated genes were
detected in 2 of the 19 patients screened for APC and MUTYH
(Table 1). One patient (370#3105) with an unspecified number
of adenomas carried the c.1100_1101delCT variant of APC, in
the alternatively spliced portion of exon 9. The same nucleotide
substitution had been previously reported to associate with
attenuated polyposis phenotypes displaying less than 10
adenomas [47]. Another patient (308#1260), with recurrent
adenomas at endoscopic follow-up, was a compound
heterozygote for the c.1145GA (p.Gly382Asp) and the c.
1395_1397delGGA (p.Glu466del) variants of MUTYH that were
previously reported as pathogenic [13].
Overall results of germline integrative analyses
The overall results of integrative germline analyses
performed in this study are summarized in Figure 2. Nucleotide
variants or rearrangements of MMR genes with a definite
pathogenic role were identified respectively in 42 (45.7%) and
15 (16.3%) of the 92 patients with ascertained germline
alterations. VUS classified as pathogenic or potentially
pathogenic based on previous studies (see Table S5) were
identified in 28 (30.4%) of the probands with ascertained
germline defects. None of the probands tested showed
germline MSH2 or MLH1 promoter methylation. Overall, the
above analyses identified pathogenic variants in 85 (92.4%) of
the probands with ascertained germline alterations. ASE
allowed the detection of pathogenic alterations in 5 (5.4%)
additional probands, including 3 negative at other screenings
and 2 bearing a VUS that caused decreased expression of the
corresponding allele. Furthermore, APC and MUTYH screening
allowed the detection of pathogenic variants in 2 (2.2%)
additional probands.
Discussion
In this study we summarize the results of extensive analyses
conducted in 132 AC probands providing insights that may help
clinical translation of genetic testing in HNPCC.
In line with other studies [3-5], the majority of the germline
MMR gene defects detected were nucleotide variants or
rearrangements in MSH2 or MLH1. Among MMR genes less
commonly mutated in HNPCC, pathogenic MSH6 variants were
identified only in 2 probands. We did not analyze either
genomic rearrangements of MSH6, which account for 5%
(17/320) of the variants of this gene reported in the June 2013
release of the Human Gene Mutation Database [48], or its
germline methylation status. Furthermore, we did not screen
PMS2 or other genes occasionally mutated in HNPCC. It is
possible that a fraction of cases negative at our analyses
carries unscreened defects in these genes. A substantial
proportion of patients (30/72 showing nucleotide changes in
MMR genes, 42%) presented VUS, such as missense variants,
Figure 2.  Results of integrative germline analyses performed in this study.  VUS included in-frame deletions, sequence
variants with uncertain effect on splicing and missense variants. Evidence of a pathogenic, possibly pathogenic defect in 28
probands with VUS derived from previous studies (see Table S5). In one additional case (360#2916) availability of RNA allowed
ASE analysis that helped to characterize a VUS shared also by another proband (986#3487, see Results). ASE analysis was
conducted in 22 individuals, including 12 with ascertained germline defect that are not shown in the figure. APC and MUTYH
screening was conducted in a subset of patients negative for MMR defects (see Methods). Inclusion of ASE analysis and screening
for APC and MUTYH sequence variants in the integrative analyses increased the number of probands with germline alterations
detected.
doi: 10.1371/journal.pone.0081194.g002
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in-frame deletions and nucleotide substitutions with uncertain
effect on splicing. Characterization of these variants is complex
and may require the use of assays that are not routinely
available [6]. To facilitate classification of VUS many algorithms
have been developed including software tools, such as MAPP-
MMR, PON-MMR and CoDP, specifically dedicated to MMR
genes [42-44,49-52]. Moreover, the pathogenic potential of
many VUS recurring in HNPCC was established in previous
studies [33-44]. In this regard, 25 of our 30 probands with VUS
carried variants that had been previously reported to be
pathogenic or possibly pathogenic (Table S5). The remaining 5
probands carried 5 novel VUS, including 3 missense variants
(2 occurring in the same proband) predicted to have a
deleterious effect using previously developed in silico tools
(see Table S5), one in-frame deletion that was considered
potentially pathogenic based on previous studies showing the
crucial function of the amino acids removed and one intronic
variant (occurring in 2 probands) whose deleterious effect on
allele expression and splicing was characterized in this study
based on the results of ASE analysis, as discussed below.
One remarkable observation in this study is the high
proportion (8/22, 36.5%) of germline defects revealed by ASE
analysis in the informative probands analyzed. Notably, in a
relevant proportion of cases ASE contributed to identify
germline alterations that were not detected by other analyses
or that were of uncertain significance (Figure 2). In particular, in
3 of these cases, negative for pathogenic variants or VUS,
imbalanced ASE was the only germline MMR gene defect
identified (Table 1). The 3 patients showed also independent
evidence of MMR defects, as indicated by the presence of
tumor MSI-H phenotype. These observations show that ASE
analysis has the potential to reveal alterations in germline
transcript expression even when these are due to defects that
may escape detection with traditional sequencing, MLPA or
NGS approaches. Such defects include germline epigenetic
allele silencing, or nucleotide changes occurring in genomic
regions not comprised in the screening, such as cis- or trans-
acting variants that alter gene regulation and lower the
expression of the corresponding allele. In addition to identifying
defects in cases negative at other integrative germline
screenings, ASE may provide evidence for the pathogenic
potential of VUS helping to characterize these variations, as
exemplified in this study by the splice site variant detected in
patients 360#2916 and 986#3487, both displaying tumor MSI-H
phenotype. For this novel VUS, in silico analyses provided
inconclusive results, whereas ASE analysis with two different
markers readily revealed a marked alteration in allelic
expression. ASE also guided the characterization of the mutant
transcript, which was initially hindered by its lower expression,
allowing the detection of exon skipping. Thus, ASE cost-
effectively complements molecular analyses in probands
negative at other screenings and may be helpful for the
characterization of VUS with potential effects on gene
expression that may be detected by gDNA-based methods,
both traditional or NGS. In fact, NGS is bound to uncover novel
coding and non-coding variants with potential effects on gene
expression and testing their functional effect appears currently
challenging [53]. In these cases, ASE may represent a practical
tool to reveal pathogenic germline alterations in the
corresponding genes.
None of the probands tested in our study had germline
MSH2 promoter hypermethylation. This epigenetic modification
was previously shown to be heritable and associated to
deletions affecting the last exon of EPCAM, but sparing the
contiguous MSH2 promoter [8,31]. In line with the lack of
germline promoter hypermethylation in our probands, the only
patient displaying an EPCAM rearrangement in this study had
a deletion that removed also the MSH2 promoter and extended
up to exon 7 of this gene. Thus, our results indicate that
EPCAM rearrangements and MSH2 promoter hypermethylation
were not frequent among the probands tested in the present
study. We did not detect germline hypermethylation of the
MLH1 promoter and this finding in our probands belonging to
families with vertical transmission is consistent with the non-
Mendelian inheritance mostly reported for constitutional MLH1
epimutations [54,55].
Several studies supported the value of tumor IHC and MSI
prescreening and these analyses are included in models for
multifactorial classification of VUS pathogenicity [6,19,44,51].
In this study, tumor IHC and MSI were generally concordant
with the results of germline analyses, but there were several
exceptions that limited their practical value. IHC provided
indications useful to target germline mutational screening in 46
of the 73 (63%) cases analyzed. In several of our probands
(12/73, 16%) the results of IHC were in contrast with those of
germline screening for MMR gene defects and/or tumor MSI
analysis. The occurrence of discrepancies between IHC, MSI
and germline screening for defects in MMR genes was
reported also in previous studies [5,19]. As far as MSI,
germline MMR gene defects were detected in the majority of
MSI-H cases and no MMR gene pathogenic variants were
detected in patients with MSS or MSI-L tumors in our study.
However, previous studies showed that patients with MSS or
MSI-L tumors may occasionally harbor germline MMR gene
defects [5,20]. Moreover, the occurrence of somatic MLH1
silencing was previously shown to be responsible of
inconsistencies between germline and tumor MMR defects [5].
In addition to the potential causes of inconsistencies described
in previous studies, we cannot exclude that technical issues,
such as sample quality and differences in IHC and MSI
procedures and interpretation among centers might be
responsible for some of the discrepancies between germline
and tumor observed in our study. In any case, the occurrence
of false positive or negative results with both IHC and MSI also
in previous studies [5,19,20] indicates that these tumor assays
should be used with caution to include or exclude probands
from screening for germline MMR gene defects. In particular, a
germline screening based on the results of IHC analyses
obtained in this study would have missed germline defects in 6
probands. Furthermore, with the advent of cost-efficient NGS
technologies, allowing simultaneous analysis of several CRC
predisposing genes, IHC and MSI prescreening may become
unnecessary. On the other hand, tumor assays, such as IHC
and MSI, may provide evidences that contribute to
multifactorial models for VUS classification, as indicated by
previous studies [43,44,52].
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One important issue in genetic testing of HNPCC is the
considerable proportion of patients negative for MMR gene
variants observed in several studies [19-21], including the
present. This reflects at least in part limitations of MMR gene
screenings that are shared by this and other studies and in part
the fact that a significant percentage (up to 40%) of families
meeting Amsterdam criteria are FCCTX unrelated to MMR
defects [4]. It is noteworthy that in our study 2 of the 19 (~10%)
probands negative for MMR gene variants and undergoing
mutation screening of APC and MUTYH carried germline
defects in one of these two genes. Thus, despite the limited
number of patients screened, this finding highlights the
importance of analyzing polyposis-associated genes in families
negative for MMR gene alterations with a clinical HNPCC
phenotype. In this regard, testing of multiple genes is now
facilitated by the use of NGS approaches [22]. On the other
hand, despite extensive screening of known CRC
predisposition genes by NGS, the genetic basis of most cases
negative for germline pathogenic defects in those genes
remains elusive, as indicated by a recent study that identified
only 6 pathogenic variants and 3 VUS among 31 Lynch or
polyposis syndrome patients negative at previous analyses
[22]. This observation indicates that NGS approaches focusing
on candidate genes improve detection of gene variants, but are
not sufficient to achieve a definite genetic diagnosis in all
probands and that further studies are necessary to clarify the
genetic basis of cases negative for pathogenic defects.
Our results provide a number of indications that may help to
improve current diagnostic algorithms for HNPCC. Analysis of
several CRC predisposing genes was necessary to reveal
germline defects and low-throughput methods are not cost-
efficient for this task, especially when IHC results do not help to
prioritize germline screening, as it occurred for several
probands in this study. The recent development of gDNA-
based NGS assays for parallel analysis of CRC predisposing
genes (including MMR genes, APC and MUTYH tested in this
study) opens a new possibility for more efficient genetic
screening of HNPCC at reasonable costs. This technology has
the potential to reveal both sequence variants and
rearrangements that are the most frequent pathogenic defects
detected in HNPCC. We screened for MMR gene
rearrangements using MLPA that may still represent a cost-
efficient approach for these relatively frequent defects.
Confirmation of putative rearrangements was obtained using
low-throughput methods, preferably by direct demonstration of
breakpoints. Considering that breakpoint determination may be
time-consuming and impractical, indirect methods may be
applied, as exemplified by a recent study that confirmed by
MLPA the putative rearrangements indicated by NGS [22]. The
use of NFMP-DHPLC or LOC-CNV for rearrangement
confirmation may represent a cost-effective alternative to
MLPA, because these methods have lower analytical costs and
assays validated in this or previous studies are already
available [28,29]. In our study none of the probands analyzed
showed germline hypermethylation of MMR gene promoters.
However, when such alterations are identified ASE analysis of
the corresponding gene may provide an independent evidence
of a pathogenic effect. In this study, ASE analysis helped to
characterize one VUS with potential effects on splicing and
revealed germline defects in 3 probands where only common
nonpathogenic variants were detected. Thus, inclusion of ASE
in our integrative screening (Figure 2) contributed to increase
the proportion of patients with germline MMR defects identified
as compared to previously proposed diagnostic algorithms that
do not include ASE [17-21].
In conclusion, this study provides an overview of some
relevant issues encountered in the genetic diagnosis of
HNPCC using a variety of methods and supports the notion
that ASE analysis and APC and MUTYH screening should be
integrated in diagnostic algorithms to improve clinical
translation of genetic testing in CRC predisposing syndromes.
Supporting Information
Figure S1.  NFMP-HPLC assays for EPCAM genomic
rearrangements. Probes for EPCAM-1 and EPCAM-2 assays
are indicated based on their position in the region
encompassing EPCAM and the 5’upstream region of MSH2
(panel a). Examples of EPCAM-1 (panel b) and EPCAM-2
(panel c) profiles are shown for control individuals (top of each
panel) and 2 representative patients (459#2809, middle of each
panel; 412#3342, bottom of each panel). Control peaks are
labeled “c” and arrows indicate amplicons with decreased peak
heights, indicative of genomic deletions. EPCAM-1 (panel b): in
patient 459#2809 the chromatographic profile shows
decreased peak heights for the 2 amplicons corresponding to
the MSH2 5’ upstream region (proximal and distal); in patient
412#3342 all the EPCAM-MSH2 amplicons included in the
assay show decreased peak heights compared to the control
peaks. EPCAM-2 (panel c): in patient 459#2809 no alterations
in the chromatographic profile are observed, confirming the
absence of deletions in the EPCAM amplicons tested; in
patient 412#33428 the peaks corresponding to the EPCAM
probes show decreased heights compared to the control
peaks, confirming the deletion of the EPCAM amplicons tested.
(TIF)
Figure S2.  Molecular analysis of exon skipping in patient
360#2916. Panel a: Location of RT-PCR primers in MLH1
exons 14 and 17. Panel b: DHPLC chomatographic profiles
obtained with cDNAs from patient 360#2916 and a control. The
chromatogram of patient 360#2916 shows a major peak
corresponding to the wt transcript and a minor peak
corresponding to a less expressed shorter transcript (average
allelic ratio 4.50, derived from 3 independent experiments).
Panel c: DHPLC profiles derived from PCR amplification of the
chromatographic fractions corresponding to the purified wt or
shorter transcript. Panel d: Sequences corresponding to the
two purified peaks (sequences of reverse strands are shown).
The longer peak displays the wildtype sequence (top
sequence), whereas the shorter peak shows the skipping of
exon 15 (bottom sequence).
(TIF)
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Table S1.  Primers for NFMP-HPLC analysis of EPCAM-
MSH2 rearrangements. The first NFMP-HPLC multiplex for
EPCAM (EPCAM-1) consisted of 7 amplicons, including 2
located in exons 3 and 8 of EPCAM, 3 located within the
intergenic MSH2-EPCAM region and 2 reference amplicons
corresponding to MSH2 exon 9 and MLH1 exon 5. The second
NFMP-HPLC multiplex for EPCAM (EPCAM-2) consisted of 4
amplicons, including 2 located in exons 8 and 9 of EPCAM and
2 reference amplicons corresponding to MSH2 exon 9 and
MLH1 exon 5. The third NFMP-HPLC multiplex for EPCAM
(EPCAM-3) differed from EPCAM-2 assay only for the
reference amplicon that was located within a copy number
invariant region in chromosome 2q36.1. Multiplex PCRs were
performed using a touchdown protocol in a total of 23 cycles.
Reactions were carried out on a GeneAmp PCR System 2720
thermocycler (Applied Biosystems), in a final volume of 10 µl
containing 30-50 ng of template DNA and 0.5 unit of AmpliTaq
Gold DNA polymerase (Applied Biosystems).
(DOC)
Table S2.  Primers for analysis of germline MLH1 promoter
methylation.
(DOC)
Table S3.  Comparison between results of ASE analyses
performed using 32P-labeled primers or DHPLC.
(DOC)
Table S4.  Primers for ASE assays developed in this study.
(DOC)
Table S5.  MSH2, MLH1 and MSH6 nucleotide variants
detected.
(DOC)
Table S6.  Analysis of genomic rearrangements.
(DOC)
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